Graft vs Host Disease: all 815 studies
Page 4 of 9. Open to participants first (138), then studies with results posted, then the rest; newest registration first within each.
- Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantCompletedNCT00691015Phase 2Results posted
- Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host DiseaseCompletedNCT00686855Phase 2Results posted
- Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)TerminatedNCT00675441Phase 2Results posted
- Montelukast to Treat Bronchiolitis ObliteransCompletedNCT00656058Phase 2Results posted
- Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell TransplantCompletedNCT00639717Phase 2Results posted
- Rapamycin for Prevention of Chronic Graft-Versus-Host DiseaseTerminatedNCT00623012Phase 1/2Results posted
- Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic CancerCompletedNCT00611351Phase 2Results posted
- Photopheresis for the Treatment of Acute Graft Versus Host DiseaseCompletedNCT00609609Phase 2Results posted
- Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate MofetilTerminatedNCT00608517Not applicableResults posted
- Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological CancerCompletedNCT00589563Phase 2Results posted
- A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and MelphalanCompletedNCT00577278Phase 2Results posted
- Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic CancerTerminatedNCT00555048Phase 1/2Results posted
- The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry EyeTerminatedNCT00553735Phase 4Results posted
- Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell TransplantationTerminatedNCT00548717Phase 2Results posted
- Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
- Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host DiseaseCompletedNCT00529035Phase 1Results posted
- Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell TransplantCompletedNCT00513474Phase 1Results posted
- Tissue Repair in Stem Cell Transplant RecipientsTerminatedNCT00501228Not applicableResults posted
- Campath in Chronic GVHDCompletedNCT00495755Phase 1Results posted
- High-Dose Cyclophosphamide for Steroid Refractory GVHDCompletedNCT00492921Phase 2Results posted
- Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous SteroidsTerminatedNCT00489216Not applicableResults posted
- Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood DiseasesTerminatedNCT00450983Phase 2Results posted
- Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other DiseaseCompletedNCT00423514Phase 1/2Results posted
- Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host DiseaseCompletedNCT00408928Phase 2Results posted
- Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantCompletedNCT00408681Not applicableResults posted
- Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)CompletedNCT00406393Phase 3Results posted
- Dexamethasone to Prevent Oral Chronic Graft-versus-Host DiseaseCompletedNCT00391170Phase 2Results posted
- Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host DiseaseCompletedNCT00388362Phase 2Results posted
- Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete RemissionCompletedNCT00382109Phase 3Results posted
- Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell TransplantationCompletedNCT00369226Phase 1/2Results posted
- Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTXCompletedNCT00360685Not applicableResults posted
- A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host DiseaseCompletedNCT00350545Not applicableResults posted
- Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell TransplantationCompletedNCT00282282Phase 2Results posted
- Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic CancerTerminatedNCT00255684Not applicableResults posted
- Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)CompletedNCT00224874Phase 2Results posted
- A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant RecipientsCompletedNCT00195429Phase 4Results posted
- Study Evaluating Sirolimus in Kidney Transplant RecipientsCompletedNCT00195273Phase 3Results posted
- Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) TransplantationCompletedNCT00189488Phase 2Results posted
- Allogeneic Transplantation From Related Haploidentical DonorsCompletedNCT00185692Phase 2Results posted
- Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)CompletedNCT00141739Phase 2Results posted
- Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell TransplantCompletedNCT00096161Phase 2Results posted
- Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)TerminatedNCT00089141Phase 3Results posted
- Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior TreatmentCompletedNCT00079183Phase 2Results posted
- Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related StomatitisTerminatedNCT00075023Phase 2Results posted
- Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host DiseaseCompletedNCT00074035Phase 2Results posted
- Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDSCompletedNCT00025662Phase 2Results posted
- Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003270Phase 2Results posted
- Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST)CompletedNCT07469865Not applicable
- Efficacy of Low-dose PT-Cy for Prevention of GVHD in Ambulatory Allogeneic HSCTCompletedNCT07319000Phase 2
- Autologous Serum Obtained by a Closed-Circuit Collection DeviceActive, not recruitingNCT07014059Phase 2
- The Safety and Efficacy of Fecal Microbiota Transplant (FMT) for Steroid-refractory Graft-versus-host DiseaseCompletedNCT06938165Not applicable
- 5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)WithdrawnNCT06598332Early Phase 1
- Donor Neutrophil Subsets to Predict the Risk of aGVHDActive, not recruitingNCT06394895
- Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host DiseaseWithdrawnNCT06200441
- Horizons Chronic Graft-Versus-Host-Disease StudyActive, not recruitingNCT06160986Not applicable
- Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT RecipientsCompletedNCT06080490
- TCRαβ/CD19 Depletion of Stem Cell Grafts for TransplantWithdrawnNCT05968170Not applicable
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese ParticipantsCompletedNCT05885451Phase 1
- A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy ParticipantsCompletedNCT05873907Phase 1
- To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative BioavailabilityCompletedNCT05856058Phase 1
- Infliximab Efficacy in Relation to Therapeutic Drug Monitoring and Serum TNFα Levels in Pediatric HSCTCompletedNCT05825833
- Safety and Clinical Activity of Itolizumab in aGVHDStatus unknownNCT05823675Phase 1
- Intestinal Microbiome-based Research for the Prevention of Acute GVHDStatus unknownNCT05808985Phase 2
- Post-transplantation Cyclophosphamide in Haploidentical Stem Cell Allografts Dose Reduction: 50 mg/kg vs 25 mg/kgStatus unknownNCT05780554Not applicable
- Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHDApproved for marketingNCT05722912
- Photopheresis in GvHD After Hematopoietic Transplantation: Characteristics of the Procedure and of the Cell ProductCompletedNCT05718674
- Expressive Writing in GVHDTerminatedNCT05694832Early Phase 1
- Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host DiseaseCompletedNCT05663827Phase 3
- A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHDTerminatedNCT05643638Phase 2
- De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) ProphylaxisActive, not recruitingNCT05622318Phase 2
- Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHDActive, not recruitingNCT05621759Phase 2
- A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in KoreaCompletedNCT05621733
- Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT ModelCompletedNCT05600855Phase 2
- In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory DiseasesCompletedNCT05544448Not applicable
- Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host DiseaseStatus unknownNCT05531266Not applicable
- Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host DiseaseWithdrawnNCT05515692Early Phase 1
- Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated CytopeniasWithdrawnNCT05509582Phase 2
- Physiotherapy and Therapeutic Exercise Program in Graft-versus-host Disease (GvHD)Status unknownNCT05401955Not applicable
- Infliximab Efficacy, TDM and Serum TNFα Levels in Pediatric HSCT Recipients With aGVHD: Prospective Observational StudyCompletedNCT05362630
- Safety and Tolerability of FMT Capsules in Healthy VolunteersStatus unknownNCT05352269Phase 1
- Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host DiseaseStatus unknownNCT05348096Phase 2
- Optoacoustic Detection of Inflammation Using MSOT DeviceTerminatedNCT05333978Not applicable
- Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHDWithdrawnNCT05333029Phase 2
- Vaginal Microbiome and the Development of Vulvovaginal Graft Versus Host DiseaseActive, not recruitingNCT05316740
- Allogeneic Platelet Lysate Eye Drops for the Treatment of Severe Chronic Ocular Graft-versus-host DiseaseCompletedNCT05311514Phase 2
- Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD TreatmentCompletedNCT05294666Phase 4
- A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)TerminatedNCT05263999Phase 3
- Evaluation of the Impact of Reduced ImmunosuppressionCompletedNCT05238155
- Metabolome and Microbiome Impact on Acute GVHD in Recipients of Hematopoietic TransplantActive, not recruitingNCT05186857
- Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD ProphylaxisStatus unknownNCT05158608Phase 3
- GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATGActive, not recruitingNCT05153226Phase 3
- Umbilical Cord Mesenchymal Stem Cells in the Treatment of Moderate/Severe Chronic Graft-versus-host DiseaseStatus unknownNCT05152160Phase 1/2
- A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host DiseaseActive, not recruitingNCT05132166Phase 2
- Study of Ruxolitinib for Acute and Chronic Graft Versus Host DiseaseCompletedNCT05121142Phase 1
- IRENE-G Study: Impact of Resistance Exercise and Nutritional Endorsement on GvHD SymptomsActive, not recruitingNCT05111834Not applicable
- Treatment of Oral Mucositis Using Platelet Rich Fibrin TREATMENT OF ORAL MUCOSITIS USING PRFCompletedNCT05018754
- MTX and Steroid for III-IV aGVHD TreatmentStatus unknownNCT04958538Phase 2
- Study on the Treatment With Water-filtered Infrared-A (wIRA) Radiation in Patients With Morphea and Sclerotic Graft-versus-host DiseaseTerminatedNCT04954573Not applicable
- Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative NeoplasmCompletedNCT04926194Phase 2
- Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin DiseasesActive, not recruitingNCT04922736Not applicable